Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

被引：34

作者：

Kosmider, Olivier ^{[1
]}

Passet, Marie ^{[1
]}

Santini, Valeria ^{[2
]}

Platzbecker, Uwe ^{[3
]}

Andrieu, Valerie ^{[4
]}

Zini, Gina ^{[5
]}

Beyne-Rauzy, Odile ^{[6
]}

Guerci, Agnes ^{[7
]}

Masala, Erico ^{[8
]}

Balleari, Enrico ^{[9
]}

Bulycheva, Ekaterina ^{[3
]}

Dreyfus, Francois ^{[10
]}

Fenaux, Pierre ^{[11
]}

Fontenay, Michaela ^{[1
]}

Park, Sophie ^{[12
]}

机构：

[1] Hop Cochin, AP HP, Hematol Biol, Paris, France

[2] Univ Florence, AOU Careggi, Hematol, I-50121 Florence, Italy

[3] Univ Hosp Carl Gustav Dresden, Dresden, Germany

[4] Hop Bichat Claude Bernard, AP HP, Hematol Biol, Paris, France

[5] Univ Cattolica Sacro Cuore, Rome, Italy

[6] Oncopole, IUCT, Toulouse, France

[7] Hop Brabois, Nancy, France

[8] Univ Florence, Florence, Italy

[9] IRCCS AOU San Martino IST Genova, Genoa, Italy

[10] Hop Cochin, Serv Hematol, Paris, France

[11] Hop St Louis, Serv Hematol Seniors, Paris, France

[12] Univ Grenoble Alpes, CHU Grenoble Alpes, Clin Univ Hematol, Grenoble, France

来源：

HAEMATOLOGICA | 2016年 / 101卷 / 07期

关键词：

myelodysplastic syndromes; cytogenetics and molecular genetics; red cells; SURVIVAL; IMPACT; MODEL;

D O I：

10.3324/haematol.2016.142695

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：280 / 283

页数：4

共 50 条

[31] Treatment of Lower Risk Myelodysplastic Syndromes MDS [J].

Komrokji, Rami .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 :S69-S70

[32] Azacitidine in lower-risk myelodysplastic syndromes [J].

Santini, Valeria .

LEUKEMIA RESEARCH, 2009, 33 :S22-S26

[33] Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebocontrolled, phase 3 trial [J].

Platzbecker, Uwe ;

Santini, Valeria ;

Fenaux, Pierre ;

Sekeres, Mikkael A. ;

Savona, Michael R. ;

Madanat, Yazan F. ;

Diez-Campelo, Maria ;

Valcarcel, David ;

Illmer, Thomas ;

Jonasova, Anna ;

Belohlavkova, Petra ;

Sherman, Laurie J. ;

Berry, Tymara ;

Dougherty, Souria ;

Shah, Sheetal ;

Xia, Qi ;

Sun, Libo ;

Wan, Ying ;

Huang, Fei ;

Ikin, Annat ;

Navada, Shyamala ;

Feller, Faye ;

Komrokji, Rami S. ;

Zeidan, Amer M. .

LANCET, 2024, 403 (10423) :249-260

[34] Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes [J].

Pavlidis, George ;

Papageorgiou, Sotirios G. ;

Bazani, Efthimia ;

Bouchla, Anthi ;

Glezou, Eirini ;

Gkontopoulos, Konstantinos ;

Thomopoulos, Thomas ;

Pappa, Vasiliki ;

Vlahakos, Demetrios V. .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12

[35] Mutations and karyotype predict treatment response in myelodysplastic syndromes [J].

Idossa, Dame ;

Lasho, Terra L. ;

Finke, Christy M. ;

Ketterling, Rhett P. ;

Patnaik, Mrinal M. ;

Pardanani, Animesh ;

Gangat, Naseema ;

Tefferi, Ayalew .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (11) :1420-1426

[36] Erythropoiesis stimulating agents and other growth factors in low-risk MDS [J].

Hellstrom-Lindberg, Eva p ;

van de Loosdrecht, Arjan .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (04) :401-410

[37] Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes [J].

Davidoff, Amy J. ;

Smith, Sheila Weiss ;

Baer, Maria R. ;

Ke, Xuehua ;

Bierenbaum, Jason M. ;

Hendrick, Franklin ;

McNally, Diane L. ;

Gore, Steven D. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (01) :128-132

[38] Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma [J].

Horvath-Puho, Erzsebet ;

Suttorp, Marit M. ;

Frederiksen, Henrik ;

Hoekstra, Tiny ;

Dekkers, Olaf M. ;

Pedersen, Lars ;

Cannegieter, Suzanne C. ;

Dekker, Friedo W. ;

Sorensen, Henrik Toft .

CLINICAL EPIDEMIOLOGY, 2018, 10 :1371-1380

[39] Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents [J].

Takahashi, Koichi ;

Patel, Keyur ;

Bueso-Ramos, Carlos ;

Zhang, Jianhua ;

Gumbs, Curtis ;

Jabbour, Elias ;

Kadia, Tapan ;

Andreff, Michael ;

Konopleva, Marina ;

DiNardo, Courtney ;

Daver, Naval ;

Cortes, Jorge ;

Estrov, Zeev ;

Futreal, Andrew ;

Kantarjian, Hagop ;

Garcia-Manero, Guillermo .

ONCOTARGET, 2016, 7 (12) :14172-14187

[40] Management of patients with lower-risk myelodysplastic syndromes [J].

Brunner, Andrew M. ;

Leitch, Heather A. ;

van de Loosdrecht, Arjan A. ;

Bonadies, Nicolas .

BLOOD CANCER JOURNAL, 2022, 12 (12)

← 1 2 3 4 5 →